FDA Requests Withdrawal of Weight-Loss Drug
On February 13th, the Food and Drug Administration (FDA) requested that drug manufacturer Eisai Inc. remove diet drugs Belviq and Belviq XR from the market after a clinical trial showed an increased occurrence of cancer in patients taking Belviq. Here, the pharmaceutical liability attorneys at Peter Angelos, P.C. discuss the FDA’s decision to request this drug be pulled from the U.S. market, and potential health risks that Belviq poses to consumers currently taking the drug.
FDA Analysis Shows Increased Cancer Risk for Belviq Users
Belviq, also known as lorcaserin, is a weight-loss drug that affects the signals in the brain that control appetite. Originally approved in 2012 by the FDA, the drug manufacturer was required to conduct an additional clinical trial evaluate Belviq’s safety. In this case control study, which compares patients taking Belviq to patients that are given a placebo, it was observed that the patients taking Belviq were diagnosed with cancer more often than those patients given a placebo. The study noted increased incidences in specific types of cancer, including pancreatic, colorectal and lung cancer.
Warning Issued for Patients and Healthcare Professionals
In addition to requesting that Eisai Inc. remove Belviq and Belviq XR from the market, the FDA directly warned patients currently taking the medication to stop immediately and safely dispose of any Belviq and Belviq XR they may still have on hand. It is critical that physicians and patients continue to monitor and report any adverse effects suffered while, or after, taking Belviq.
Discuss Your Options With a Pharmaceutical Liability Attorney at Peter Angelos, P.C.
It is vital to our public health that patients who are negatively affected by dangerous prescription drugs come forward and report their experiences. Doing so may prevent others from suffering life-altering injuries and illnesses in the future. If you or a loved one has been adversely affected by Belviq or Belviq XR, schedule a free consultation with the Law Offices of Peter Angelos P.C. today.